01 / 01
Use → or click to advance  ·  O contents  ·  B appendix

Contents

← → move  ·  ↵ jump  ·  esc close
Main deck 00
Appendix 00
EC331  ·  Research in Applied Economics

Innovation, protection, or strategic play?

The Effect of AI Patent Application on Company Performance: Evidence from North American Firms


Fasai Charoensudjai
Department of Economics · University of Warwick (2022–2025)
Warwick Economics Academic and Research Community
RAE Showcase & Idea Exchange
Context

Everyone wants to be
“AI-powered”.

But is it worth it to protect an AI innovation?

Context

A crash course on patents

AI patent filings rose sharply between 1991 and 2020, led by the United States and China1, and use spread well beyond the technology sector into pharmaceutical innovation2. Whether that growth pays is an empirical question, and it matters to firms and to policy in different ways.

01Patents?

Patents are a class of intellectual property granting a legal right to exclude others from using a new invention, but only once granted. Innovation drives long-run growth, so patents exist to make that innovation worth pursuing.

Schumpeter, 1983 · Shapiro, 2007
02So what?

Patents are also signalling tools. Firms file to attract investors, strengthen a negotiating position with partners, and demonstrate value to host-country governments.

An et al., 2023 · Blind et al., 2006 · Zhou et al., 2023
03IP & AI?

With AI, the boundaries blur. Who owns an AI-generated invention? Can a process be patented? Subject-matter eligibility is unsettled, and the rules are still being written.

Müller, 2024 · Hickey and Zirpoli, 2024
Why this matters

For firms, it decides whether a filing is worth its cost. A granted patent can defend a market, a refused one is a fee paid for nothing. For policy, it tests rules that assume a patent creates value while inventorship and eligibility are unsettled.

1Liu et al., 2021 2Rathi, Majumdar and Chatterjee, 2024
Literature review

What have people said?

There is no shortage of work on patents and firm performance. It pools AI with every other patent, treats patent counts as a proxy for adoption, or reads the legal rules without testing them – and almost none of it asks what filing an AI patent does to the firm that files.

Study Headline finding Limit of the design

Helmers and Rogers

2011 · UK

Filers grow assets faster than non-filers.

  • Selection by controls, not matching
  • Application and grant never separated

Taglialatela and Barontini

2024 · Italy

Applications lift sales for up to three years.

  • AI pooled with non-AI
  • Cohorts pooled

Yang

2022 · Taiwan

AI adoption raises productivity and employment.

  • AI patents proxy for adoption
  • Two-way fixed effects, no cohort weights

Marioni, Rincon-Aznar and Venturini

2024 · Europe

Gains are largest furthest from the frontier.

  • Patents as an indicator, not an asset
  • Productivity, not firm value

Müller; Hickey and Zirpoli

2024

AI eligibility narrowed through the 2010s.

  • Describes the rules, tests nothing
  • No firm outcome, no filing link
My Contribution
  • Research – AI patents treated as an IP category of their own and matched against non‑AI patents on the same design, so the estimates separate AI innovation from innovation in general. North America, where recent AI patenting growth has concentrated, and measured at application as well as at grant.
  • Methodological – cohort weights in PSM–DID in place of pooled cohorts, and a neural network in place of logit or probit when estimating propensity scores.
The question

How does AI patenting affect firm performance?

Most studies treat filing and grant as one thing. They cost a firm completely different amounts — filing is money spent on a bet, and the grant is what you get if it lands.

Outcome

EBITDA is the internal measure — what the business actually earns, before financing and accounting conventions. Revenue and market value sit alongside it as the external measures of what customers buy and what investors expect.

Treatment

A firm's AI patenting activity — either applying or being granted. Filing sets t = 0, and outcomes are traced either side of it, so parallel trends are tested rather than assumed.

Comparisons

Two effects I want to pull apart. The application effect, filers against firms that never file. The grant effect, granted applicants against applicants who weren’t. Then whether either looks different for AI patents than for non‑AI ones — in case AI has something special about it.

Data

Constructing the firm panel

Through fuzzy matching, a further match on city and postcode, and filtering, the applicants that come out are not comparable with the firms they are measured against.

15.4m
USPTO AI Patent Datasetpatent documents, 1976–2023, classified for AI
10.5m
USPTO Patent Assignment Datasetwho actually owned the patent
50,000+
Compustat Annual Fundamentalsfirm financials, 2006–2024
1.6–10k
Matched panelobservations per specification
Before any matching
applicants non-applicants

Firms that file an AI patent are already larger and more profitable than the firms they would be compared against, so a like-for-like comparison does not exist in the raw data.

EBITDA, $m
534vs409
Revenue, $m
4,185vs2,780
Size, log assets
6.68vs5.42

The matched data then went through the filtering procedures and propensity score matching (more on that later!).

Methodology

Identification strategy & NN‑PSM

A cohort event study in modern microeconometrics, matched by a neural network.

The regressionviolet = this card's termit decides the sampleviolet = this card's termviolet = this card's term
Yits = αi + δt + ∑c=1T−1 ∑j=1−cT−1−c  βc,j 1{s = j} × 1{Si = c} + X′iγ + εits
Y = EBITDA · revenue · market value i = firm × filing, t = year s = years since filing, c = cohort, j = event year X = firm controls
Difference in differences01
01

Difference in differences

The estimand
β = ΔY(Treat = 1) − ΔY(Treat = 0)
filing filed did not
Parallel before, divergent after
  • αi is fixed per firm and filing, so permanent differences drop out and a second application is its own unit
  • δt is a year fixed effect, so common shocks drop out
  • βc,j is what survives, and is valid only if both groups would have moved together
  • Treated and control swap — applicants against non‑filers gives the application effect, granted against non‑granted gives the grant effect

Leaves behind selection: filers are already larger, and already growing faster.

Propensity matching02
02

Propensity matching

The score
p̂(Xi) = fNN(Xi)
1 · train 2 · tune 3 · match score 0 score 1
Train, then tune, then match on the score
  • Logit and probit force a form on covariates that interact; misspecification biases every score
  • The network learns that form instead, with two hidden layers
  • Tuned by black‑box Bayesian optimisation; out-of-sample AUC 0.70–0.81
  • The score is the probability of applying, not of being granted

Leaves behind timing: matched pairs still sit in one pooled regression.

AUC is the chance the score ranks a random filer above a random non‑filer. 0.5 is a coin toss; 0.70–0.81 is high for a behavioural outcome. Matched separately means each design draws its own controls — filers against non‑filers, granted against not‑granted, AI against non‑AI. The same application score is reused for all three, which is exact for the first and an approximation for the grant effect. Hornik et al. 1989 · Setoguchi et al. 2008 · Brochu et al. 2010 · Orbach et al. 2023

Cohort weighting03
03

Cohort weighting

The cohort ATT
τATT(c, s) = E[Yi,c+s(c) − Yi,c+s(∞) | Si = c]
cohort weight 2012 2016 2019
Post-treatment shaded, bar is weight
  • Cohorts differ: 2012 and 2019 filers met different markets, adoption rates, macro conditions
  • Already‑treated firms act as controls, so αi + δt weights cohorts by variance, some negative, and β need not average to real effects
  • So I estimate β per cohort c and event year j (the double sum), then weight by cohort size

Leaves behind reverse causality: a strong year may be what prompts the filing, so which way the cause runs stays open.

A cohort is the set of firms first treated in the same year; never‑treated firms are the comparison throughout. The problem is the weighting, not that the cohorts differ. Implemented as Sun and Abraham: each cohort on its own event time, weighted by size, no firm used as a control once treated. Sun & Abraham 2021 · de Chaisemartin & D'Haultfœuille 2020 · Goodman‑Bacon 2021

Sample restriction04
04

Sample restriction

The sample
S = { first filing; no filings in t−2, t−1 },  j ∈ [−3, +7]
−3 −2 −1 0 +1 +2 +3 filing no filings in t−2, t−1
Rebased to t−3, no prior filings
  • First-time filers only, or no filings in the two prior years, so Yits is observed for a defined set of firm-years
  • Closes the route from a good year to the filing
  • Rebased to t−3, so anticipation shows as a pre‑trend

Closes the sequence: what remains is what the design cannot reach.

Result

Headline figures

Pooled across both stages, AI patenting nets to zero. Separated, application destroys operating value and grant creates it — and both effects are large.

−$0.00m
Applied, not granted
EBITDA destroyed six years on.
+$0.00m
Granted · year before
Value created before the grant issues.
+$0.00m
Granted · seven years on
The gap widens rather than closing.
Result

A closer look

EBITDA at event time, rebased to t−3. Application and grant, read against the same axis.

EBITDA · spec. (2) · applied, not granted, vs non‑filers
Event study of EBITDA on applicants who were not granted against matched non-filers. No pre-treatment coefficient is significant; estimates fall steadily after treatment.
EBITDA · spec. (3) · granted, vs non‑granted
Event study of EBITDA on granted applicants against matched non-granted applicants. No pre-treatment coefficient is significant; estimates rise steadily after treatment.

No coefficient before treatment is significant in either panel, so the turn at the boundary is the treatment rather than a trend already in motion.

Result

Beyond the headline

EBITDA is the only outcome that responds to a grant. And the technology only matters once it is granted.

By outcome
Market value
No effect
No significant AI application or grant effect. Non‑AI grants are followed by modest declines.
Revenue
Volatile
AI applicants out‑earn non‑AI applicants by $2.79bn by year six. AI grants then fall $7.02bn by year seven, consistent with firms shedding legacy products.
By patent type
Applied, AI vs non‑AI
No difference
Applicants that were not granted do not separate on EBITDA, whichever technology they filed in.
AI grant
Immediate
EBITDA responds from the year before issue and climbs to +$308.79m by year six.
Non‑AI grant
Delayed
EBITDA only at year seven, and revenue gains $0.87–0.92bn at years six and seven.
Robustness & limitations

What held, and what is assumed

Held
✓
Parallel trends
EBITDA: no pre‑treatment coefficient is significant, in any of the six specifications. Market value: clean across the five years before treatment, bar a t−12 blip.
✓
Covariate balance
Matching improved balance in most specifications. SHAP ranks finance, IT and communications as the likeliest AI filers.
✓
Multicollinearity
VIFs checked on every model. Leverage dropped because it moved with the other financial controls.
Not held
✗
Parallel trends
Revenue fails in specifications (5) and (6), so those estimates are reported as descriptive.
✗
Grant matching
Granted and non‑granted applicants are matched on application propensity, not grant propensity.
✗
Name matching
Patent holders and Compustat firms share no identifier, so the fuzzy match across millions of records left many applicants unmatched, and the sample is a fraction of the filing population.
✗
Power
The no‑filing filter and the matching both remove observations, so a null is not evidence of no effect.
Future work

Estimate grant propensity directly, conditional on application, rather than borrowing the application score. Test whether the two‑year buffer is long enough, and set the network against logit and probit on the same covariates. Above all, establish what actually determines patenting.

So what

You only get paid if it's granted

Filing without a grant costs $300.70m of EBITDA by year six. Getting one adds $308.79m, and the gap keeps widening.

AI patents pay back sooner than non‑AI patents

EBITDA responds before an AI grant even issues. A non‑AI grant does not move it until year seven.

The two effects have to be read separately

Added together, the loss from filing and the gain from the grant cancel out. That gives you a non-effect, when in reality both things are happening.

EC331  ·  Research in Applied Economics

Thank you.

Questions, challenges and counter-arguments welcome. The six specifications, the network and the matching diagnostics are one key away — press B.


Fasai Charoensudjai
Department of Economics · University of Warwick (2022–2025)
Warwick Economics Academic and Research Community
RAE Showcase & Idea Exchange
Appendix · A1

The six specifications

Which firms count as treated changes with the question. That gives six specifications, each run on three outcomes — EBITDA, revenue and market value. 18 regressions.

Spec.
Timing
Treated
Control
Effect
(1)
Application year
AI applicants
AI non‑filers
Application, grants included
(2)
Application year
AI not granted
AI non‑filers
Application, grants excluded
(3)
Grant year
AI granted
AI not granted
Grant
(4)
Application year
AI applicants
Non‑AI applicants
AI against non‑AI, grants included
(5)
Application year
AI not granted
Non‑AI not granted
AI against non‑AI, grants excluded
(6)
Grant year
Non‑AI granted
Non‑AI not granted
Grant, non‑AI
Why (2) and (5)

Some firms apply and then get granted, so (1) and (4) have a grant sitting inside the treated group. (2) and (5) take the grantees out, and what is left is the application on its own.

Appendix · A2

The propensity network

A neural network stacks layers of neurons, each taking a weighted sum of the layer below and bending it through a nonlinearity. Big enough stacks approximate almost any continuous function, so the score here is learnt from key firm variables and their lags instead of assumed.

Fundamentals in, one probability per threshold out
Feedforward network: covariates into a hidden layer of 122 nodes, a second of 101, then three sigmoid outputs for the 50, 86 and 93 classification thresholds.
Inputs
size, cash flow, leverage, age, sector · t−1 to t−3
Hidden layers
122 · 101
Activation
ReLU
Dropout
0.2
Optimiser
Adam · lr 0.01
Batch · epochs
64 · 30
Heads
p50 · p86 · p93
Validation AUC
0.811
Held‑out AUC
0.79

Training. An 80/20 stratified split, ReLU hidden layers, dropout 0.2 against memorising the firms it has seen, and Adam for faster convergence. Because only about a quarter of patenting firms are treated, the model is scored on AUC‑ROC rather than accuracy. The nine settings were picked by black‑box Bayesian optimisation. A Gaussian process is fitted to the validation AUC already observed, expected improvement chooses each next configuration, and 75 evaluations do the work a grid search would need thousands for.

Appendix · A3

Matching quality

What matching did to the covariates, and what the network was reading when it scored a firm.

Covariate balance before and after matching · spec. (5)
Standardised differences for each covariate before and after matching, specification 5. Most covariates move towards zero; a few deteriorate slightly.
SHAP values from the propensity network, ranked
Bar chart of SHAP values from the propensity network, ranked by importance. Finance, information and communication services raise the probability of filing; firm age lowers it.

Balance. Matching improves balance on the key covariates in most specifications. Specification (5) deteriorates on a few variables, though parallel trends for EBITDA holds regardless, and that is what the estimates rely on.

Plausibility. Finance, information and communication-services firms are the most likely to apply, and older firms the least. The ranking matches economic intuition, which is the only check available here, and the mechanisms behind it are not identified.